Hikma to keep its injectables arm

Hikma Pharmaceuticals said yesterday it would keep its fast-growing injectables business after announcing a review of third-party interest in the business in March. The Jordan-based group said it had noted the significant amount of interest shown, but thinks keeping the firm is in the best interests of shareholders. Shares in the group fell 6.9 per cent to 917.5p.

Related articles